Kisqali® (ribociclib)
for Breast Cancer

Kisqali (ribociclib) is a targeted therapy used to treat HR-positive, HER2-negative breast cancer in adults. It is prescribed with an aromatase inhibitor for high-risk early breast cancer or advanced breast cancer that has worsened or spread. Kisqali works by inhibiting cyclin-dependent kinases 4 and 6 (CDK4/6), which regulate cell growth, helping to slow or stop cancer progression. It is not chemotherapy but a targeted treatment.

Heart
Other top medicines used to treat Breast Cancer